MEDTRONIC VASCULAR GALWAY UNLIMITED COMPANY
Location
Founded
1989-12-19
Website
Risk Signals
4968 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Surgical and Medical Instruments and Apparatus, Drugs, Drug Proprietaries, and Druggists' Sundries), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about MEDTRONIC VASCULAR GALWAY UNLIMITED COMPANY
Live alerts from global media, monitored by Business Radar
2025-04-24 (koreabiomed.com)
Medtronic's drug-coated balloon for dialysis patients to be reimbursed in Korea starting May < Device/ICT < Article -
Medtronic said Thursday its IN.PACT AV drug-coated balloon catheter (DCB) will be reimbursed in Korea starting in May for use in dialysis patients who experience early re-narrowing of their vascular access site.The device is used to treat stenotic lesions -- narrowed blood vessels -- in patients wit
Read more
2025-03-12 (bosa.co.kr)
Medi ThinQ, W12.4bn 'Series B' Investment Success <Medical Device · IT <Article Body-
[Medical Newspaper, Daily Reporter = Choi Jin -wook] MedithinQ (CEO Lim Seung -jun) announced on the 11th that it has succeeded in attracting the 'series B', which is worth 12.4 billion won, exceeding the original target. Medi ThinQ plans to spur the domestic and overseas market by utilizing this investment. Partners Investment participated as a lead investor in this investment, and domestic and foreign venture capital (VC) and strategic investors were together.Medi ThinQ signed a US monopoly supply contract with Medtronic last year and its representative product, SCOPEYE.
Read more